Statistics from Altmetric.com
van der Heijde D, Schiff M, Tanaka Y, et al. Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis. RMD Open 2019;5:e000898. doi: 10.1136/rmdopen-2019-000898
The authors want to alert readers to the following errors in regard to Figure 3.
In panels A (mTSS) and B (ES) for the RA-BEGIN graphs, the symbol (‡) indicating the significance level for the comparison between the baricitinib 4-mg and baricitinib 4-mg plus MTX treatment groups (denoting p≤0.05) should be over the 1 year time point, not the 2 year time point in both graphs.
In panel A (mTSS) for RA-BEAM, for the adalimumab versus placebo comparison at 2 years, the significance should have been shown as ++ (p≤0.01) and not +++ (p≤0.001).
In the Results text, p.8, line 12 (relating to Figure 3, panel A) ‘…baricitinib treatment groups (0.21±0.01…’ should read: ‘…baricitinib treatment groups (0.21±0.10…’
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.